More consolidation today? It sure feels that way right now with a flat pre-market. I'm still looking for a break of the tight trading range of the last two sessions.
On Today's Calendar:
- 10:00 -- New Home Sales
More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic
Potential swing trades:
See one of the recent 'Chart Reading' posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
Gapping down on weak earnings/guidance: GVHR -6.4%, AGR -3.8% (merger partner LSI -2.6% also down in sympathy)... Other news: PGIC -12.4% (discloses co to report trading irregularities), BEC -8.7% (acquires Biosite for a 53% premium; also downgraded to Mkt Perform at Piper), CVTX -6.7% (downgraded to Sell at Deutsche), HNAB -6.2% (further weakness following Friday's plunge), SNCR -3.7% (downgraded to Accumulate at ThinkEquity), TELN -2.6% (downgraded overseas), BSX -2.6% (Heart stents failed 'Courage' test - WSJ; also downgraded to Mkt Perform at BMO), LEND -2.3% (Morgan Stanley auctioning $2.48 bln of mortgages from NEWC.PK - New York Post), PKX -2.0% (Nippon Steel has "no concrete plans" to raise PKX stake; also PKX says it's plan for developing coal in Heilongjiang, China delayed).
Gapping Up
Gapping up on strong earnings/guidance: NVTL (will likely trade up following guidance when it resumes trading at 9:00 ET; no indication yet -- up in sympathy SWIR +4.2%)... M&A: BSTE +51.5% (to be acquired by Beckman for $85/share), TRB +4.8% (Zell's bid for Tribune said to be favored - LA Times)... Other news: ALXA +49.1% (AZ-004 Phase IIa trial meets primary endpoint in treating schizophrenic patients with acute agitation), OSIR +28.5% (announced yesterday positive results in stem cell trial to treat heart disease; up in sympathy on light volume STEM +5.4%, ASTM +4.4%, GERN +3.3%, VIAC +2.1%), IDEV +8.0% (reports that interim review of NEBIDO Phase III data indicates trial is likely to meet primary endpoints), BQI +7.5% (momentum), ISIS +7.1% (announced yesterday new data presented at ACC show ISIS-301012 monotherapy reduces apoB to undetectable levels, reduces LDL-C 70%), GROW +6.6% (announces Friday afternoon that U.S. Global Investors Resources and Gold Funds win 2007 Lipper Fund awards), MEND +6.4%, ALU +5.4% (Verizon Wireless awards ALU an expected $6 bln contract for ongoing network expansion), EPL +4.7% (commences $23/share self-tender offer for 8.7 mln shares), HOKU +4.2% (momentum), DNDN +4.0% (momentum), PDLI +3.5% (upgraded to Overweight at Prudential), BRCD +3.6% (positive comments by Cramer), ABT +3.5% (announces positive six-month results from stent trial; also positive analyst comments).
Disclaimer & How I use this list
